• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 1, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

AACR: Adavosertib speeds cancer cells into the wall of mitotic catastrophe

Bioengineer by Bioengineer
April 1, 2019
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: University of Colorado Cancer Center

A cancer cell is like a racecar, speeding through the process of cellular replication. But it has to stop at the G2M cell cycle checkpoint, where a race inspector called Wee1 checks it over for damage – cells with intact DNA can continue, while cells with damaged DNA have to stick around for repairs. The wait is worth it – there are curves ahead, and beyond the G2M checkpoint, cells with damaged DNA explode against the wall of “mitotic catastrophe.” But the thing is, we want cancer cells to explode; we would rather they speed through the G2M checkpoint without a Wee1 inspection and hit the wall of mitotic catastrophe.

A University of Colorado Cancer Center study presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 suggests a way to ensure that cancer cells with damaged DNA fly past G2M to their doom: Blindfold the race inspector. By inhibiting the action of Wee1, cancer cells blow right through the G2M checkpoint and are doomed by their damaged DNA to mitotic catastrophe.

The Wee1 inhibitor adavosertib is used in a number of previous and ongoing clinical trials. However, the drug’s effectiveness has overall been promising but not perfect. The goal of the current study was to test drugs in combination with adavosertib that might magnify its effect. Specifically, the study hoped to find new combinations against pancreatic cancer, which carries a prognosis of less than 7 percent 5-year survival.

“The way the grant was focused was to utilize the list of the drugs in the NCI’s Cancer Therapy Evaluation Program (CTEP) and figure out what drugs might work together with adavosertib against pancreatic tumors,” says Todd Pitts, PhD, investigator at CU Cancer Center and assistant research professor in the CU School of Medicine Division of Medical Oncology.

More broadly, the work of the Pitts lab is at the cutting edge of a developing strategy against cancer, namely the manipulation of cells’ ability to repair damaged DNA. Commonly, DNA damage repair fixes mutations that could cause cancer. In other words, “DNA damage repair is usually a good thing,” Pitts says. But when the cells being repaired are cancer cells, the “good” outcome switches from repair to destruction.

Pitts and colleagues including study first author Sarah Hartman, MS, ended up testing the following drugs/combinations: adavosertib, irinotecan, navitoclax, capecitabine, adavosertib + irinotecan, or adavosertib + navitoclax, adavosertib + capecitabine. After using cell cultures to determine optimal doses, the researchers tested these drugs and drug combinations on PDX models of pancreatic cancer – basically, human tumors grown on mice.

The most successful combinations were adavosertib with irinotecan, navitoclax or capecitabine.

“The Wee1 inhibitor and navitoclax have overlapping toxicities, so we don’t believe that combination will move forward clinically. But the irinotecan and capecitabine combos could move forward,” Pitts says.

In fact, the group recently submitted a letter of intent to start a clinical trial of combination adavosertib with capecitabine. “There will always be some toxicity from a Wee1 inhibitor, but capecitabine is very well tolerated, so we think adavosertib with capecitabine would be a well-tolerated combination,” Pitts says.

###

Media Contact
Garth Sundem
[email protected]

Tags: BiologycancerClinical TrialsInternal MedicineMedicine/HealthPharmaceutical ChemistryPharmaceutical SciencePharmaceutical Sciences
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Moffitt Cancer Center Initiates Study to Enhance Advanced Lung Cancer Outcomes in Black Patients

August 1, 2025
Breakthrough in Melanoma Guidance System Offers New Hope to Halt Metastasis

Breakthrough in Melanoma Guidance System Offers New Hope to Halt Metastasis

August 1, 2025

Scientists Uncover How Leukemia Virus Remains Dormant in the Body – Paving the Way for Future Therapies

August 1, 2025

Final Clinical Trial Results Published for Advanced Kidney Cancer Therapy

August 1, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    37 shares
    Share 15 Tweet 9
  • Sustainability Accelerator Chooses 41 Promising Projects Poised for Rapid Scale-Up

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Melanthiaceae Genomes Reveal Giant Genome Evolution Secrets

Tracking Tumor DNA During Gastric Cancer Treatment

Heparan Sulfate Protein Improves MPS IIIB Symptoms

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.